As of November 7, 2026, Agomab Therapeutics NV is a publicly traded company (Nasdaq: AGMB). The largest holder reporting an active stake on Schedule 13D is LSP 7 Cooperatieve U.A., at 10.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (10%), Pontifax VI G.P. L.P. (6.8%), Sanofi (5.71%) (Schedule 13D, February 17, 2026).
Is this your company?
About to sign with, pay or invest in Agomab Therapeutics NV? See the free Snapshot first.
Free to see. No signup.
Is Agomab Therapeutics NV a real, registered company?
- AgomAb Therapeutics NV files with the SEC under CIK 2020932 (its SEC filings).
- Its shares are listed under the ticker AGMB on Nasdaq (SEC company record).
- Incorporated in C9, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under AgomAb Therapeutics NV in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Redmile Group, LLC (filed 2026-05-15).
Who are Agomab Therapeutics NV's owners and officers?
Agomab Therapeutics NV: industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-05-15).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-05-15 | Redmile Group, LLC | 5.6% |
| Schedule 13G, 2026-05-15 | Cormorant Asset Management, LP | 5.01% |
| Schedule 13G, 2026-05-06 | Sanofi | 5.71% |
| Schedule 13G, 2026-04-16 | Pontifax Vi G.P. L.P. | 6.8% |
| Schedule 13G, 2026-03-06 | Fmr LLC | 10% |
| Schedule 13D, 2026-02-17 | Lsp 7 Cooperatieve U.A. | 10.6% |
Questions about who owns Agomab Therapeutics NV
Who owns Agomab Therapeutics NV?
On this page, 6 holders' latest ownership filings report 5% or more of Agomab Therapeutics NV: Lsp 7 Cooperatieve U.A. (10.6%, Schedule 13D, filed 2026-02-17), Fmr LLC (10%, Schedule 13G, filed 2026-03-06), Pontifax Vi G.P. L.P. (6.8%, Schedule 13G, filed 2026-04-16), Sanofi (5.71%, Schedule 13G, filed 2026-05-06) and Redmile Group, LLC (5.6%, Schedule 13G, filed 2026-05-15); 1 more is listed above.
Who are the largest shareholders of Agomab Therapeutics NV?
By the share each holder's latest filing reports, the largest holders of Agomab Therapeutics NV on this page are Lsp 7 Cooperatieve U.A. (10.6%), Fmr LLC (10%) and Pontifax Vi G.P. L.P. (6.8%).
When did Lsp 7 Cooperatieve U.A. buy into Agomab Therapeutics NV?
The filings give report dates, not purchase dates. The earliest filing from Lsp 7 Cooperatieve U.A. on this page is the Schedule 13D, filed 2026-02-17, reporting 10.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Agomab Therapeutics NV?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Agomab Therapeutics NV: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Agomab Therapeutics NV covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Agomab Therapeutics NV shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 56,217 shares (0.16% of shares outstanding), 21,823 held directly and 34,394 indirectly (Form 4, 2026-10-07).
- , a director: 40,000 shares (0.12% of shares outstanding) (Form 4, 2026-11-06).
- , the chief financial officer: 10,000 shares (0.03% of shares outstanding) (Form 4, 2026-10-07).
Shares outstanding: 34,167,168 as of 2025-12-31, from the company's latest SEC cover page.
How much has Agomab Therapeutics NV raised?
Latest IPO step: Agomab Therapeutics NV filed its final IPO prospectus, ticker AGMB (424B4, 2026-02-06).
IPO filings: 424B4, 2026-02-06, F-1/A, 2026-01-29, F-1, 2026-01-16; ticker AGMB on Nasdaq Global Select Market.
Keep reading
More on Agomab Therapeutics NV and the records around it.
Agomab Therapeutics NV elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- LSP 7 Cooperatieve U.A. also filed stake reports on 3 other companies: Electra Therapeutics, Inc. (Sep 2026), Oculis Holding AG (Apr 2026), Evommune, Inc. (Feb 2026)
- Pontifax VI G.P. L.P. also filed stake reports on 3 other companies: Keros Therapeutics, Inc. (Oct 2025), LB Pharmaceuticals Inc (Sep 2025), Climb Bio, Inc. (Sep 2025)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/agomab-therapeutics-nv